{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:00:16Z","timestamp":1793037616214,"version":"4.5.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,2,14]],"date-time":"2013-02-14T00:00:00Z","timestamp":1360800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,2,14]],"date-time":"2013-02-14T00:00:00Z","timestamp":1360800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s10637-013-9939-6","type":"journal-article","created":{"date-parts":[[2013,2,13]],"date-time":"2013-02-13T12:17:17Z","timestamp":1360757837000},"page":"1071-1077","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":205,"title":["Ipilimumab associated hepatitis: imaging and clinicopathologic findings"],"prefix":"10.1007","volume":"31","author":[{"given":"Kyung Won","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil H.","family":"Ramaiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine M.","family":"Krajewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyothi P.","family":"Jagannathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sree Harsha","family":"Tirumani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitabh","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nageatte","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,2,14]]},"reference":[{"issue":"8","key":"9939_CR1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711\u2013723. doi:10.1056\/NEJMoa1003466","journal-title":"N Engl J Med"},{"issue":"5","key":"9939_CR2","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1053\/j.seminoncol.2010.09.015","volume":"37","author":"A Hoos","year":"2010","unstructured":"Hoos A, Ibrahim R, Korman A et al (2010) Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol 37(5):533\u2013546. doi:10.1053\/j.seminoncol.2010.09.015","journal-title":"Semin Oncol"},{"issue":"2","key":"9939_CR3","doi-asserted-by":"publisher","first-page":"W241","DOI":"10.2214\/AJR.10.6032","volume":"197","author":"KN O\u2019Regan","year":"2011","unstructured":"O\u2019Regan KN, Jagannathan JP, Ramaiya N, Hodi FS (2011) Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy. AJR Am J Roentgenol 197(2):W241\u2013W246. doi:10.2214\/AJR.10.6032","journal-title":"AJR Am J Roentgenol"},{"key":"9939_CR4","doi-asserted-by":"publisher","unstructured":"Weber JS, Kahler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. doi:10.1200\/JCO.2012.41.6750","DOI":"10.1200\/JCO.2012.41.6750"},{"issue":"5","key":"9939_CR5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1053\/j.seminoncol.2010.09.007","volume":"37","author":"AM Di Giacomo","year":"2010","unstructured":"Di Giacomo AM, Biagioli M, Maio M (2010) The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 37(5):499\u2013507. doi:10.1053\/j.seminoncol.2010.09.007","journal-title":"Semin Oncol"},{"issue":"6","key":"9939_CR6","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1097\/RLU.0b013e318248549a","volume":"37","author":"A Lyall","year":"2012","unstructured":"Lyall A, Vargas HA, Carvajal RD, Ulaner G (2012) Ipilimumab-induced colitis on FDG PET\/CT. Clin Nucl Med 37(6):629\u2013630. doi:10.1097\/RLU.0b013e318248549a","journal-title":"Clin Nucl Med"},{"issue":"6","key":"9939_CR7","doi-asserted-by":"publisher","first-page":"W992","DOI":"10.2214\/AJR.10.6198","volume":"197","author":"Y Bronstein","year":"2011","unstructured":"Bronstein Y, Ng CS, Hwu P, Hwu WJ (2011) Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am J Roentgenol 197(6):W992\u2013W1000. doi:10.2214\/AJR.10.6198","journal-title":"AJR Am J Roentgenol"},{"issue":"4","key":"9939_CR8","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1148\/rg.244035719","volume":"24","author":"KJ Mortele","year":"2004","unstructured":"Mortele KJ, Segatto E, Ros PR (2004) The infected liver: radiologic-pathologic correlation. Radiographics 24(4):937\u2013955. doi:10.1148\/rg.244035719","journal-title":"Radiographics"},{"issue":"8","key":"9939_CR9","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s10620-012-2140-5","volume":"57","author":"DE Kleiner","year":"2012","unstructured":"Kleiner DE, Berman D (2012) Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig Dis Sci 57(8):2233\u20132240. doi:10.1007\/s10620-012-2140-5","journal-title":"Dig Dis Sci"},{"issue":"14","key":"9939_CR10","doi-asserted-by":"publisher","first-page":"8372","DOI":"10.1073\/pnas.1533209100","volume":"100","author":"GQ Phan","year":"2003","unstructured":"Phan GQ, Yang JC, Sherry RM et al (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 100(14):8372\u20138377. doi:10.1073\/pnas.1533209100","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"9939_CR11","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1093\/annonc\/mdq013","volume":"21","author":"SJ O\u2019Day","year":"2010","unstructured":"O\u2019Day SJ, Maio M, Chiarion-Sileni V et al (2010) Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 21(8):1712\u20131717. doi:10.1093\/annonc\/mdq013","journal-title":"Ann Oncol"},{"issue":"9","key":"9939_CR12","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1200\/JCO.2010.32.2206","volume":"29","author":"KD Chmiel","year":"2011","unstructured":"Chmiel KD, Suan D, Liddle C et al (2011) Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol 29(9):e237\u2013e240. doi:10.1200\/JCO.2010.32.2206","journal-title":"J Clin Oncol"},{"key":"9939_CR13","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1600-065X.2008.00604.x","volume":"222","author":"MA Cheever","year":"2008","unstructured":"Cheever MA (2008) Twelve immunotherapy drugs that could cure cancers. Immunol Rev 222:357\u2013368. doi:10.1111\/j.1600-065X.2008.00604.x","journal-title":"Immunol Rev"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-9939-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-013-9939-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-9939-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-9939-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:36:45Z","timestamp":1678509405000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-013-9939-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,14]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["9939"],"URL":"https:\/\/doi.org\/10.1007\/s10637-013-9939-6","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,14]]},"assertion":[{"value":"4 December 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}